Showing results (1551-1560 of 3,525) with videos related to

Sort By:
Pageof 353
Thoracic Cancer|May 3, 2021
ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case reportKeisuke Yamamoto, Gouji Toyokawa, Yuka Kozuma, et al.
Thoracic Cancer|May 3, 2021
Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cellsKakeru Hisakane, Masahiro Seike, Teppei Sugano, et al.
Thoracic Cancer|May 4, 2021
Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case reportTomoki Tamura, Keita Kawakado, Go Makimoto, et al.
Thoracic Cancer|May 5, 2021
Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non-small cell lung cancerXin Nie, Ping Zhang, Jia-Yin Gao, et al.
Thoracic Cancer|May 5, 2021
Current status and perspectives of spread through air spaces in lung cancerToshihiro Ikeda, Kyuichi Kadota, Tetsuhiko Go, et al.
Thoracic Cancer|May 18, 2021
Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumabShinkichi Takamori, Nobuki Furubayashi, Kenichi Taguchi, et al.
Thoracic Cancer|May 19, 2021
KIN17 promotes tumor metastasis by activating EMT signaling in luminal-A breast cancerQiyuan Huang, Kashif Rafiq Zahid, Jinsi Chen, et al.
Thoracic Cancer|May 2, 2021
BAI1 nuclear expression reflects the survival of nonsmoking non-small cell lung cancer patientsHyo Jung An, Sung Hwan Kim, Jung Wook Yang, et al.
Thoracic Cancer|June 12, 2020
Combination effects of ellagic acid with erlotinib in a Ba/F3 cell line expressing EGFR H773_V774 insH mutationChuanqi Xie, Jindong Kong, Fujun Miao, et al.
Thoracic Cancer|June 5, 2020
Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trialNobuaki Kobayashi, Hisashi Hashimoto, Chisato Kamimaki, et al.
Pageof 353